Literature DB >> 12429307

Impact of a second transurethral resection on the staging of T1 bladder cancer.

Guido Dalbagni1, Harry W Herr, Victor E Reuter.   

Abstract

OBJECTIVES: To evaluate the impact of a second transurethral resection (TUR) on the pathologic stage in a unique patient population with T1 tumors.
METHODS: Seventy-one patients with Stage T1 transitional cell carcinoma of the bladder were prospectively enrolled and underwent restaging TUR. Fifteen patients underwent immediate cystectomy and 56 patients were treated endoscopically. The patients who underwent immediate cystectomy were the subjects of this report.
RESULTS: Fifteen patients underwent immediate cystectomy. At restaging TUR, 13 patients had persistent T1, 1 patient had Tis, and 1 patient had no residual disease. The pathologic stage at cystectomy revealed the presence of residual disease in 12 of 15 patients, and 3 patients had pT0. Of the 12 patients with residual disease, 3 had residual pT1, 2 had pT1 with pTis, 5 had pTis alone, and 2 had muscle-invasive tumors. Thirteen percent of the patients who underwent immediate cystectomy after restaging TUR had a pathologic stage greater than pT1.
CONCLUSIONS: Understaging for T1 disease is negligible after restaging TUR.

Entities:  

Mesh:

Year:  2002        PMID: 12429307     DOI: 10.1016/s0090-4295(02)01920-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  18 in total

1.  Choosing earlier therapy for muscle-invasive bladder cancer.

Authors:  John P Stein
Journal:  Rev Urol       Date:  2005

2.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 3.  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.

Authors:  Miguel Ramírez-Backhaus; José Domínguez-Escrig; Argimiro Collado; José Rubio-Briones; Eduardo Solsona
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 4.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

Review 5.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

6.  T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.

Authors:  E De Berardinis; G M Busetto; G Antonini; R Giovannone; V Gentile
Journal:  Int Urol Nephrol       Date:  2011-03-29       Impact factor: 2.370

7.  Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder.

Authors:  Massimiliano Spaliviero; Guido Dalbagni; Bernard H Bochner; Bing Ying Poon; Hongying Huang; Hikmat A Al-Ahmadie; Timothy F Donahue; Jennifer M Taylor; Joshua J Meeks; Daniel D Sjoberg; S Machele Donat; Victor E Reuter; Harry W Herr
Journal:  J Urol       Date:  2014-03-03       Impact factor: 7.450

8.  Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy.

Authors:  Jacob T Ark; Kirk A Keegan; Daniel A Barocas; Todd M Morgan; Matthew J Resnick; Chaochen You; Michael S Cookson; David F Penson; Rodney Davis; Peter E Clark; Joseph A Smith; Sam S Chang
Journal:  BJU Int       Date:  2014-04-03       Impact factor: 5.588

Review 9.  Use of nomograms as predictive tools in bladder cancer.

Authors:  Ahmad Shabsigh; Bernard H Bochner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

10.  Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta.

Authors:  Geoffrey T Gotto; Melissa A Shea-Budgell; J Dean Ruether
Journal:  Can Urol Assoc J       Date:  2016 Jan-Feb       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.